Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Hydrocodone | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Magnesium sulfate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Atracurium besylate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Mirtazapine | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Orphenadrine | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Pramipexole | Atracurium besylate may increase the sedative activities of Pramipexole. |
| Ropinirole | Atracurium besylate may increase the sedative activities of Ropinirole. |
| Rotigotine | Atracurium besylate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Atracurium besylate. |
| Sodium oxybate | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Thalidomide | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Capreomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Capreomycin. |
| Cyclosporine | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Cyclosporine. |
| Doxycycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Doxycycline. |
| Lymecycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Lymecycline. |
| Framycetin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Framycetin. |
| Clomocycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Clomocycline. |
| Quinine | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Quinine. |
| Vancomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Vancomycin. |
| Tigecycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tigecycline. |
| Oxytetracycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Oxytetracycline. |
| Chloroquine | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Chloroquine. |
| Demeclocycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Demeclocycline. |
| Mecamylamine | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Mecamylamine. |
| Tobramycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tobramycin. |
| Tetracycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tetracycline. |
| Gentamicin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Gentamicin. |
| Etacrynic acid | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Etacrynic acid. |
| Quinidine | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Quinidine. |
| Metacycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Metacycline. |
| Netilmicin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Netilmicin. |
| Neomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Neomycin. |
| Streptomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Streptomycin. |
| Colistimethate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Colistimethate. |
| Kanamycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Kanamycin. |
| Rolitetracycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Rolitetracycline. |
| Magnesium oxide | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium oxide. |
| Magnesium cation | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium cation. |
| Paromomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Paromomycin. |
| Lincomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Lincomycin. |
| Ribostamycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Ribostamycin. |
| Geneticin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Geneticin. |
| Apramycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Apramycin. |
| Gentamicin C1a | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Gentamicin C1a. |
| Neamine | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Neamine. |
| Arbekacin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Arbekacin. |
| Viomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Viomycin. |
| Puromycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Puromycin. |
| Magnesium hydroxide | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium hydroxide. |
| Magnesium trisilicate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium trisilicate. |
| Magnesium chloride | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium chloride. |
| Magnesium acetate tetrahydrate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium acetate tetrahydrate. |
| Magnesium carbonate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium carbonate. |
| Magnesium citrate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium citrate. |
| Magnesium glycinate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium glycinate. |
| Magnesium Aluminum Silicate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Aluminum Silicate. |
| Dihydrostreptomycin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Dihydrostreptomycin. |
| Hygromycin B | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Hygromycin B. |
| Sisomicin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Sisomicin. |
| Plazomicin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Plazomicin. |
| Magnesium silicate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium silicate. |
| Penimepicycline | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Penimepicycline. |
| Magnesium aspartate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium aspartate. |
| Isepamicin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Isepamicin. |
| Magnesium gluconate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium gluconate. |
| Magnesium orotate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium orotate. |
| Magnesium phosphate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium phosphate. |
| Magnesium acetate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium acetate. |
| Procainamide | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Procainamide. |
| Dantrolene | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Dantrolene. |
| Piperacillin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Piperacillin. |
| Magnesium stearate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium stearate. |
| Colistin | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Colistin. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Atracurium besylate. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Atracurium besylate. |
| Spironolactone | Spironolactone may increase the neuromuscular blocking activities of Atracurium besylate. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum toxin type B. |
| Ethanol | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Atracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sertraline. |